Legend Biotech Corporation(LEGN) Stock Research - Grey Stern Research
Loading...

Legend Biotech Corporation (LEGN) Stock Analysis

$45.16 (-2.61%)

LEGN Financial Performance


Use the table below to view Legend Biotech Corporation's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2023

Metric Value Ranking among Peers
Price $46.37 -
52 Week Low $42.08 -
52 Week High $77.32 -
Market Cap $8.5 Billion 4/19
Gross Margin 59% 10/19
Profit Margin -100% 11/19
EBITDA margin -152% 13/19
Q3 - 2023 Revenue $79.5 Million 5/19
Q3 - 2023 Earnings -$144.8 Million 16/19
Q3 - 2023 Free Cash Flow $0 Million 19/19
Trailing 4 Quarters Revenue $285.1 Million 5/19
Trailing 4 Quarters Earnings -$518.3 Million 15/19
Quarterly Earnings Growth -145% 18/19
Annual Earnings Growth -897% 19/19
Quarterly Revenue Growth 215% 2/19
Annual Revenue Growth 166% 3/19
Cash On Hand $1.3 Billion 1/19
Short Term Debt $3.2 Million 8/19
Long Term Debt $281.3 Million 4/19

Legend Biotech Corporation Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Legend Biotech Corporation's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 1/19
PS 29.64 6/19
PB 6.72 8/19
PC 6.61 13/19
Liabilities to Equity 0.47 5/19
ROA -0.28 5/19
ROE -0.41 10/19
Current Ratio 3.13 12/19
Quick Ratio 2.22 12/19
Long Term Debt to Equity 0.22 5/19
Debt to Equity 0.26 5/19
Burn Rate 8.15 1/19
Cash to Cap 0.15 6/19
CCR 19/19
EV to EBITDA -61.98 14/19
EV to Revenue 26.31 7/19

Company Details

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

CEO: Dr. Yuan Xu Ph.D.

Website: https://www.legendbiotech.com

Address: 2101 Cottontail Lane Somerset, NEW JERSEY

Exchange: NASDAQ Global Select

Industry: Biotechnology

Legend Biotech Corporation Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Legend Biotech Corporation. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Alnylam Pharmaceuticals, Inc. ALNY $18.9 Billion
Seagen Inc. SGEN $43.2 Billion
Mirati Therapeutics, Inc. MRTX $4.1 Billion
Madrigal Pharmaceuticals, Inc. MDGL $4.7 Billion
Blueprint Medicines Corporation BPMC $6.6 Billion
Apellis Pharmaceuticals, Inc. APLS $5.0 Billion
Zai Lab Limited ZLAB $1.9 Billion
Ascendis Pharma A/S ASND $6.9 Billion
IVERIC bio, Inc. ISEE $5.5 Billion
Karuna Therapeutics, Inc. KRTX $12.6 Billion
Stoke Therapeutics, Inc. STOK $724.5 Million
89bio, Inc. ETNB $849.1 Million
Pliant Therapeutics, Inc. PLRX $921.2 Million
Vaxcyte, Inc. PCVX $8.1 Billion
Travere Therapeutics, Inc. TVTX $461.3 Million
Terns Pharmaceuticals, Inc. TERN $381.6 Million
Day One Biopharmaceuticals, Inc. DAWN $1.4 Billion
Arcellx, Inc. ACLX $2.9 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
LEGN Income Statements
Quarter Year Revenue Earnings
Q4 2023 $ 79.5 Million -$144.8 Million
Q3 2023 $ 96.0 Million -$62.2 Million
Q2 2023 $ 73.3 Million -$199.1 Million
Q1 2023 $ 36.3 Million -$112.1 Million
Q4 2022 $ 25.2 Million $319.9 Million
Q3 2022 $ 27.4 Million -$85.0 Million
Q2 2022 $ 12.0 Million -$193.2 Million
Q1 2022 $ 40.8 Million -$41.1 Million

View All

LEGN Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2023 $1.3 Billion $1.8 Billion $328.7 Million $1.3 Billion
Q3 2023 $963.5 Million $1.8 Billion $320.5 Million $1.3 Billion
Q2 2023 $1.2 Billion $1.9 Billion $318.6 Million $1.4 Billion
Q1 2023 $660.1 Million $1.2 Billion $314.8 Million $653.2 Million
Q4 2022 $19,000 $1.3 Billion $26,000 $744.3 Million
Q3 2022 $0 $0 $0 $0
Q2 2022 $379.8 Million $1.0 Billion $195.7 Million $562.6 Million
Q1 2022 $377.8 Million $1.0 Billion $129.2 Million $438.6 Million

View All

LEGN Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2023 -$66.3 Million -$5.5 Million -$269.7 Million
Q2 2023 -$95.7 Million $0 $573.2 Million
Q1 2023 -$141.1 Million $0 -$126.0 Million
Q4 2022 -$57.3 Million -$7.5 Million -$26.7 Million
Q3 2022 -$73.8 Million -$1.7 Million $433.0 Million
Q2 2022 -$1.3 Million -$559,000 $2.0 Million
Q1 2022 -$91.2 Million -$12.5 Million -$311.2 Million
Q4 2021 -$69.5 Million $0 $350.6 Million

View All